Regulatory Alerts

Keep up-to-date with key announcements and guidance from organisations including NICE, DHSC and MHRA.

Drug Safety Update: dapagliflozin (Forxiga) no longer authorised for treatment of type 1 diabetes mellitus

The authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged.
Go to the profile of OnMedica
Dec 10, 2021